Tirzepatide Dosing: Units vs. mg and Dose Adjustment Guide

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Tirzepatide is dosed in milligrams (mg), not units. A standard tirzepatide maintenance dose ranges from 5 mg to 15 mg weekly by subcutaneous injection. Understanding this dosing framework and how to interpret dose escalation schedules is essential before starting treatment.

Dosing precision matters for safety and efficacy. Individual factors—including body composition, baseline metabolic markers, gastrointestinal tolerance, and genetic predispositions in GLP-1 and GIPR pathways—may influence how a patient responds to dose escalation. A provider-guided personalized approach supports better outcomes and reduces adverse event risk.

How Tirzepatide Dosing Works: Milligrams and Titration Schedule

Tirzepatide doses are expressed in milligrams (mg) and given as a once-weekly subcutaneous injection. Unlike some medications measured in units, tirzepatide has a fixed-dose titration schedule: starting at 2.5 mg weekly, escalating by 2.5 mg at four-week intervals, up to a maximum of 15 mg weekly.

The titration approach allows the body to adapt to the medication while providers assess tolerability and efficacy at each dose level. Most patients reach a maintenance dose of 5–10 mg weekly, though individual treatment plans vary based on clinical goals and metabolic response.

Tirzepatide Dose Escalation Timeline and Clinical Benchmarks

The standard dose escalation pathway spans 12–16 weeks to reach maintenance dosing. Each four-week interval allows time to evaluate gastrointestinal adaptation, weight/metabolic response, and tolerance before advancing. This measured approach reflects clinical trial evidence and provider best practices for optimizing outcomes.

Week Range	Dose (mg)	Clinical Focus
Weeks 0–4	2.5 mg weekly	Initial tolerability; GI adaptation
Weeks 4–8	5.0 mg weekly	Efficacy assessment; sustained tolerance
Weeks 8–12	7.5–10.0 mg weekly	Optimization for metabolic goals
Weeks 12+	10.0–15.0 mg weekly	Maintenance; long-term safety monitoring

Why Individual Dose Response Varies: Genetics and Biomarkers

Not all patients escalate on the same timeline. Variations in GLP-1R and GIPR gene expression, baseline insulin resistance, liver function, and gastrointestinal motility influence how quickly someone tolerates dose increases. Biomarker assessment can contextualize individual response patterns.

A provider may slow escalation for patients with lower baseline metabolic flexibility or those experiencing nausea at standard intervals. Conversely, some individuals tolerate faster progression. Genetic predispositions in peptide pathways may provide context for these differences, supporting more tailored dosing conversations.

Safety Considerations and When to Adjust or Pause Escalation

Gastrointestinal side effects—nausea, vomiting, constipation—are common during dose escalation. Most resolve within 1–2 weeks; however, persistent severe nausea warrants provider contact. Dehydration risk increases with tirzepatide, requiring consistent fluid intake and monitoring of kidney function, especially in patients with pre-existing renal or hepatic disease.

Dose escalation is not mandatory if current dosing achieves clinical goals. A provider may maintain a patient at 5 mg or 7.5 mg if metabolic targets are met and tolerability is good. Conversely, if escalation is needed, some patients benefit from extended intervals between dose increases to minimize gastrointestinal burden.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines predispositions in the GLP1R and GIPR genes—key receptors for tirzepatide action. Variants such as GLP1R rs6923761 may help provide context for how efficiently your body's receptors respond to tirzepatide signaling, supporting a more informed discussion with your provider about dose timing and escalation strategy.

The genetic test also evaluates FTO and MC4R pathways relevant to metabolic regulation and appetite signaling. These predispositions do not predict your exact tirzepatide response, but they can help contextualize why you may tolerate certain doses differently than others or why metabolic targets may require individualized dose adjustment.

When interpreted alongside clinical markers—fasting glucose, HbA1c, liver and kidney function, baseline BMI—genetic insights support a more personalized conversation with your provider about whether standard escalation timelines suit your specific physiology and treatment goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the most affordable GLP-1 option for tirzepatide dosing: units vs. mg and dos?

PlexusDx offers compounded semaglutide starting at $149/mo and a Microdose GLP-1 Protocol from $129/month — both from licensed 503A compounding pharmacies, with no membership fee.

Does PlexusDx serve patients in all 50 states?

Yes. PlexusDx serves all 50 states. Five states require a scheduled live video consultation before the first prescription is issued; all others use async intake.

How does genetic testing improve GLP-1 outcomes?

Variants like GIPR rs1800437 affect GIP receptor function and predict differential response to tirzepatide versus semaglutide. PlexusDx's Precision Peptide Genetic Test evaluates 150+ relevant variants to guide medication selection.

Is compounded semaglutide the same as Wegovy or Ozempic?

Compounded semaglutide uses the same active ingredient but is not FDA-approved. It is prepared under federal compounding regulations at licensed 503A compounding pharmacies.

Can I use HSA or FSA funds to pay for PlexusDx?

Yes. Prescription GLP-1 medications from PlexusDx are HSA/FSA eligible with a valid prescription. PlexusDx accepts HSA and FSA cards directly at checkout.